Trial Rescue & Reconnaissance

Biorasi, a global CRO specializing in trial rescue, partnered with Citeline to stabilize a Phase III oncology study facing high site decline and screening hurdles. To turn the program around, they implemented a comprehensive feasibility assessment that analyzed clinical workflows, site capabilities, and real-world patient movement. This approach allowed the team to pressure-test planning assumptions and identify why eligible patients were not successfully completing the screening process.
By scoring 1,000 sites against 23 variables—including competitive trial burden and historical performance metrics—the strategy produced a shortlist of 260 top-tier organizations. The analysis validated 89% of the sponsor’s current sites while identifying 199 new, high-quality US opportunities and eight priority countries for expansion, such as Spain, Australia, and South Korea. Grounding site selection in this deep level of clinical intelligence provided the necessary rationale to optimize the protocol and expand the site network. These insights help sponsors reduce enrollment risk and navigate peak competitive windows where multiple trials vie for the same patient population